Siegfried AG: Company Market Research Report

Company Overview

Name and Mission of the Company

• Name: Siegfried AG

• Mission: Taking innovations to industrial scale with an extensive background in pharmaceuticals and chemicals, Siegfried is a leading contract development and manufacturing organization (CDMO).

Foundation Details

• Founded: 1873

• Founders: Pharmacist Samuel Benoni Siegfried

Key People

• Current CEO: Marcel Imwinkelried (Effective September 1, 2024)

• Interim CEO and CFO: Dr. Reto Suter

• Chairman of the Board of Directors: Andreas Casutt

Headquarter and Locations

• Headquarters: Untere Brühlstrasse 4, 4800 Zofingen, Switzerland

• Global Network: 13 production sites on three continents (Switzerland, Germany, Spain, France, Malta, the USA, and China)

Number of Employees

• Employees: More than 3,700 (as of December 31, 2023)

Revenue

• 2023 Revenue: CHF 1.272 billion

Recognition and Known For

• Known For: Trusted partner in the pharmaceutical industry for development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms.

• Industry Impact:

• Supplies approximately 200 out of 1500 FDA-approved APIs.

• Manufactures over 100 million doses of Covid-19 vaccines.

• Commitment to sustainability with inclusion in the Dow Jones Sustainability Index Europe and MSCI 'AA' rating.

Products and Services

Products Offered

1. Drug Substances (APIs and Intermediates)
2. Finished Dosage Forms

• Tablets, capsules, sterile vials, ampoules, cartridges, ointments

High-Level Product Descriptions and Key Features

• Drug Substances:

• Development and production of custom-made and generic APIs.

• Services include process development, optimization, registration, production, and packaging.

• Facilities in locations such as Zofingen, Evionnaz, St. Vulbas, and others.

• Finished Dosage Forms:

• Oral solids (tablets and capsules), sterile injectables (vials and ampoules), ophthalmics, and inhalation products.

• Development, pilot scale, and commercial manufacturing.

• Facilities in locations such as Barcelona, Hameln, and Irvine.

Key Features of Each Product

• APIs:

• Extensive scientific and technical excellence.

• Focus on sustainable production processes.

• Fully integrated services from development to commercial manufacturing.

• Finished Dosage Forms:

• High potency formulation.

• In-depth formulation technology expertise.

• State-of-the-art development centers and facilities.

Recent Developments

Recent Developments in the Company

1. New Appointments:

• Marcel Imwinkelried appointed as CEO effective September 1, 2024.

• Management team changes with Dr. Klaus Stingl and Martin Kessler assuming new roles.

2. Facility Expansions:

• Inaugurated new quality control lab in Minden (August 30, 2024).

• New development center for Drug Substances in Evionnaz set to open in Q4 2024.

• Construction ongoing for large-scale production plants in Minden.

3. Strategic Acquisitions:

• Acquisition of an early-phase CDMO in Wisconsin, USA (July 2024).

• Acquired 95% stake in DINAMIQS, focusing on viral vector manufacturing for gene therapy (May 2023).

New Products Launched

• No information is available.

New Features Added to Existing Products

• No information is available.

Partnerships and Collaborations

• No information is available.

Conclusion

Siegfried AG continues to demonstrate robust growth, drive innovation, and maintain its status as a premier partner in the pharmaceutical industry. The company's investments in new facilities and strategic acquisitions indicate a commitment to expanding capabilities and increasing operational efficiency. With the appointment of new leadership and continuous investments, Siegfried is well-positioned for future growth and sustainability.